Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is listed today as Milestone Pharmaceuticals Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2018 | $80 M | No. 3 | $50 to $250 million | equity | SEC | |
| Jul 2017 | $7 M | No. 2 | $2 to $10 million | equity | SEC | |
| Jun 2015 | $4 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Milestone Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2018).
SEC Form D · Oct 2018
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Oct 2018
That is all the official record says: Milestone Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Milestone Pharmaceuticals Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| BDC Capital Inc. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Fonds De Solidarite Des Travailleurs Du Quebec | Person | not stated | not stated | Held Series A-1, A-2, B, C and D-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Philippe Douville | Person | not stated | not stated | Held preferred stock (Form 3, 2019) | SEC Form 3 |
| RTW Investments, LP | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.
Largest shareholders today
Institutions holding Milestone Pharmaceuticals Inc. shares, as of Sep 30, 2026.
- Propel Bio Management, LLC$8 M7.59%
- Pavaki Capital Management LLC$8 M7.50%
- RTW Investments, LP$7 M6.29%
- Point72 Asset Management, L.P.$5 M4.39%
- Simplify Asset Management Inc.$3 M2.69%
- Millennium Management LLC$2 M1.80%
- Two Sigma Investments, LP$1 M1.38%
- Kalehua Capital Management LLC$1 M1.33%
- RVW Wealth, LLC$1 M0.92%
- Marshall Wace, LLP$1 M0.90%
- Lion Point Capital, LP$1 M0.66%
- Toronto Dominion Bank$1 M0.60%
- Ameriprise Financial Inc$1 M0.54%
- Boxer Capital Management, LLC$1 M0.54%
- Morgan Stanley$1 M0.50%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Douglas G. Wight | Executive officer | Oct 2018 |
| Francis G. Plat | Executive officer | Oct 2018 |
| Guy G. Rousseau | Executive officer | Oct 2018 |
| Harish G. Pimplaskar | Executive officer | Oct 2018 |
| Jeff G. Nelson | Executive officer | Oct 2018 |
| Joseph G. Oliveto | Executive officer | Oct 2018 |
| Lorenz G. Muller | Executive officer | Oct 2018 |
| Philippe G. Douville | Executive officer | Oct 2018 |
| Martin G. Maguire | Executive officer | Jul 2017 |
| Benjamin Cowen | Executive officer | Jun 2015 |
| Douglas Wight | Executive officer | Jun 2015 |
| Francis Plat | Executive officer | Jun 2015 |
| Martin Maguire | Executive officer | Jun 2015 |
| Nathalie Beauregard | Executive officer | Jun 2015 |
| Paul Truex | Executive officer | Jun 2015 |
| Philippe Douville | Executive officer | Jun 2015 |
| Debra G. Liebert | Director | Oct 2018 |
| Joseph G. Oliveto | Director | Oct 2018 |
| Marco G. Boorsma | Director | Oct 2018 |
| Nilesh G. Kumar | Director | Oct 2018 |
| Paul G. Truex | Director | Oct 2018 |
| Dion G. Madsen | Director | Jul 2017 |
| Scott G. Weiner | Director | Jul 2017 |
| Yves G. Rosconi | Director | Jul 2017 |
| Debra Liebert | Director | Jun 2015 |
| Ela Borenstein | Director | Jun 2015 |
| Paul Truex | Director | Jun 2015 |
| Philippe Douville | Director | Jun 2015 |
| Scott Weiner | Director | Jun 2015 |
| Yves Rosconi | Director | Jun 2015 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.